VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray designed to provide rapid onset of action for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”). With an estimated 20 million people in the United States suffering from SAD, it is one of the most prevalent mental health conditions in the country. VistaGen also has second neuroactive nasal spray in development; PH10 (“PH10”) is designed for potential rapid onset treatment of major depressive disorder (“MDD”) and other depressive disorder. Currently no FDA-approved, fast-acting, as-needed treatment for SAD exists. FDA-approved antidepressants and off-label use of benzodiazepines are often prescribed for the disorder, and they have potential for significant side effects. “We are committed to developing and commercializing new-generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders,” said VistaGen CEO Shawn Singh in a recent article. “The COVID-19 pandemic is causing a mental health crisis the likes of which we have never seen before, with alarming increases in anxiety, stress, depression and suicide. . . . Stress-provoking episodes are soaring, especially as routines are being disrupted, and we’ve seen skyrocketing prescriptions of benzodiazepines, which carry with them the potential for misuse, abuse and addiction, even when taken at recommended dosages.”
To view the full article, visit https://ibn.fm/iafWL
About VistaGen Therapeutics Inc.
VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php